05:42 PM EST, 01/27/2025 (MT Newswires) -- Akero Therapeutics ( AKRO ) said Monday it has started an underwritten public offering of $300 million of shares, with J.P. Morgan, Morgan Stanley and Jefferies as book-running managers.

The underwriters will be given a 30-day option to buy up to an additional $45 million of shares, the clinical-stage company said.